ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 30, 2009-- ImmunoGen, Inc. (Nasdaq:IMGN) will host a conference call at 4:30 pm ET on Thursday, August 6, 2009 to discuss the Company’s financial results for the three-month period and fiscal year ended June 30, 2009. Management also will provide an update on the Company.
To access the live call by phone, dial 913-981-4900. No passcode is required. The call also may be accessed through the Investor Information section of the Company’s website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through August 13, 2009.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and linkage of potent cancer-cell killing agents (CKAs) to such antibodies. The Company’s proprietary Targeted Antibody PayloadTM (TAP) technology consists of ImmunoGen’s highly potent CKAs, which have been designed specifically for delivery by antibodies to cancer cells, and the Company’s engineered linkers, which direct the activation of the CKA inside a cancer cell. Compounds utilizing the TAP technology are in clinical testing through ImmunoGen’s own programs and its collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen.
Source: ImmunoGen, Inc.
ImmunoGen, Inc.
Carol Hausner,781-895-0600
Executive Director, Investor Relations
and Corporate Communications
info@immunogen.com
